NOTE: The clinical term for these studies is PrEP, which stands for Pre-Exposure Prophylaxis. All of the following studies involve PrEP. The studies with the soonest expected date of completion are the Ford Health System (June 30, 2020) and Duke University (July 2020).

Duke University: HERO HCQ Study

• Patient-Centered Outcomes Research Institute committing $50 million

• double-blind, placebo-controlled, randomized trial with treatment course of 30 days.

• 15,000 patients at 17 locations in 12 states

• Principal investigator: Adrian Hernandez, M.D., cardiologist and executive director of Duke Clinical Research Institute

• Estimated primary completion date: July 2020

University of Minnesota with Rising Pharmaceuticals, Inc.

• 3,500 healthcare workers or household contacts exposed to Covid-19.

• Randomized, controlled and quadruple blinded

• Principal investigator: Radha Rajasingham, MD

• Expected completion date: August 2020.

NYU Langone Health

• 350 participants, health care workers (HCWs) at high risk of occupational exposure to SARS-CoV-2

• Controlled but non-randomized

• Principal investigator: Howard Belmont

• Expected date of completion: Aug. 1, 2020

Henry Ford Health System, Dearborn Michigan

• 3,000 participants: healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus drivers (DDOT) in SE, Michigan

• Randomized and triple blinded

• Principal investigator: William W. O’Neill

• Expected completion date: June 30, 2020.

Oxford University

• Randomized, double-blinded, controlled study in healthcare workers throughout Asia, Africa and Europe

• Workers in Europe and Africa will receive hydroxychloroquine

• Workers in Asia will receive chloroquine

• 40,000 participants

• Expected date of completion: April 2021

• Principal contact: William Schilling, MD